Option chain shows key data for Minerva Neurosciences's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Minerva Neurosciences.

Minerva Neurosciences (NASDAQ:NERV) Stock, Option Chain

Minerva Neurosciences

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Earnings

Earnings Beats

News

Penny Stocks

Health Care

Small Cap

Markets

Analyst Ratings

Trading Ideas

General

ALXO

NERV

RHHBY

SRPT

Roche (OTC: RHHBY) announced that the European Commission has granted marketing authorization to the subcutaneous formulation of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) drug Ocrevus (ocrelizumab).

Roche&#39;s Ocrevus Subcutaneous Gets European Commission Nod

Biotech

ACRV

MRNS

RARE

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), along with partner Mereo BioPharma (MREO), announced new positive 14-month data from the phase II portion of the phase II/III Orbit study evaluating setrusumab (UX143) in patients with osteogenesis imperfecta.

Ultragenyx Posts New Data From Bone Disease Study

CADL

KRYS

Candel Reports Upbeat Data From Lung Cancer Study

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences Inc

NERVGEN PHARMA CORP by NervGen Pharma Corp.

NervGen Pharma Corp

NerveNetwork

Nervos Network

Press Releases

Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates

Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates

Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

AIM ImmunoTech

Aprea Therapeutics

BioCardia

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

Channel Therapeutics Corporation Common Stock

Channel Therapeutics

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech

Geovax Labs

Imunon

Immuron Limited - American Depositary Shares

Immuron

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

MetaVia

Mainz Biomed

Ocean Biomedical

Organovo Holdings

BiomX

PharmaCyte Biotech

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Sensei Biotherapeutics, Inc. - Common Stock

Comments

Minerva Neurosciences

Minerva Neurosciences (NERV) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga